secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-07-05T23:59:59+00:00
Accession:  0001104659-23-078072
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics approved to transfer stock listing from Nasdaq Global Select to Capital Market on July 6
--------------------------------------------------------------------------------

- Received Nasdaq approval on July 3, 2023 to transfer listing from Global Select to Capital Market.
- Transfer becomes effective at the opening of business on July 6, 2023.
- Aprea's common stock (APRE) will continue trading on the Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923078072/0001104659-23-078072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923078072/tm2320610d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-078072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer